Multiple trials have demonstrated the efficacy of EGFR-TKIs in EGFR-mutated NSCLC patients in promoting response and prolonging survival compared to standard chemotherapy [4, 5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.